NCT03489525 - MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

May 8, 2018

Primary Completion Date

March 21, 2022

Study Completion Date

March 21, 2022

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

BIOLOGICAL

Dose Escalation, MEDI2228, ADC (antibody drug conjugate)

Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels

BIOLOGICAL

Dose Expansion, MEDI2228, ADC (antibody drug conjugate)

Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.

Trial Locations (11)

3004

Research Site, Melbourne

11528

Research Site, Athens

22031

Research Site, Fairfax

28204

Research Site, Charlotte

32224

Research Site, Jacksonville

48201

Research Site, Detroit

55905

Research Site, Rochester

85054

Research Site, Phoenix

02114

Research Site, Boston

02215

Research Site, Boston

08916

Research Site, Badalona